Aquatic Capital Management LLC Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Aquatic Capital Management LLC grew its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 201.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 235,414 shares of the biopharmaceutical company's stock after purchasing an additional 157,214 shares during the quarter. Aquatic Capital Management LLC owned about 0.08% of Amicus Therapeutics worth $2,218,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Wellington Management Group LLP grew its holdings in Amicus Therapeutics by 18.8% during the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock valued at $268,112,000 after purchasing an additional 4,497,950 shares during the period. Norges Bank acquired a new stake in Amicus Therapeutics during the 4th quarter worth $29,033,000. Rock Springs Capital Management LP lifted its holdings in Amicus Therapeutics by 107.9% during the fourth quarter. Rock Springs Capital Management LP now owns 2,599,425 shares of the biopharmaceutical company's stock worth $24,487,000 after acquiring an additional 1,349,145 shares in the last quarter. Renaissance Technologies LLC grew its stake in Amicus Therapeutics by 174.1% in the fourth quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company's stock valued at $19,863,000 after acquiring an additional 1,339,316 shares during the period. Finally, Trexquant Investment LP increased its holdings in shares of Amicus Therapeutics by 101.6% in the fourth quarter. Trexquant Investment LP now owns 966,049 shares of the biopharmaceutical company's stock worth $9,100,000 after acquiring an additional 486,827 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. The Goldman Sachs Group decreased their price objective on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Friday. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. UBS Group raised their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday. Finally, Wells Fargo & Company reduced their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Stock Down 0.1 %

NASDAQ:FOLD traded down $0.01 during trading hours on Friday, reaching $6.67. The company had a trading volume of 6,371,892 shares, compared to its average volume of 2,692,364. Amicus Therapeutics, Inc. has a twelve month low of $6.20 and a twelve month high of $12.65. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of -37.06, a P/E/G ratio of 1.51 and a beta of 0.79. The business's 50-day simple moving average is $7.95 and its two-hundred day simple moving average is $9.27.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.